Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Northland Capital Partners View on the City - Savannah Resources (LON:SAV); Evgen Pharma (LON:SAV);

Northland Capital Partners View on the City - Savannah Resources (LON:SAV); Evgen Pharma (LON:SAV);

Metallurgical Results from Mina do Barroso



  • Savannah Resources’ reports the results of the Phase 2 metallurgical test work at the Mina do Barroso Lithium Project, located in Portugal. Results indicate a conventional process route combining gravity and flotation will result in a total recovery of at least 80% and produce a concentrate grade of over 6% Li2O.
  • 40% of the contained lithium can be recovered via gravity processing and 70% of lithium not recovered by gravity can be recovered by flotation. Phase 3 of the test work programme currently underway.
  • Noel O'Brien, a metallurgist and lithium processing expert with over 35 years' experience has been appointed as a technical consultant to direct Savannah's metallurgical test work programme.
  • From Friday - Oman: Savannah has now received all eight required Government permitting approvals for the Maqail South Mining Licence application and seven for Mahab 4 and only the Ministry of Housing remaining. Positive discussions are continuing with the Ministry of Housing in respect of this.


Metallurgical results are an important part of any development programme with poor recoveries from conventional processing routes leading to other higher capex and opex processing routes. Importantly for Savannah, results from the test work completed to date indicates that the lithium mineralisation at Mina do Barroso is suitable to high recoveries from conventional methods and the resulting product is a conventional marketable product with low contaminants. Savannah has appointed a highly experienced lithium metallurgist to direct the Phase 3 metallurgical programme to ensure the test work is robust.




Savannah Resources is an energy metals group with copper-gold projects located in Oman, lithium projects in Portugal, and a operates a mineral sands project in Mozambique that is a JV with Rio Tinto

Update on novel sulforaphane analogues




  • Evgen gives an update on the screening of 41 novel analogues of sulforaphane, a naturally-occurring compound (derived from Brassica vegetables) which has potential therapeutic properties in several diseases. Evgen received exclusive global rights to the analogues from the University of Seville in 2015.
  • Researchers at the University of Liverpool evaluated the analogues for their toxicity against breast-cancer cells and their ability to activate Nrf2, a protein which may have a key role in sulforaphane's mechanism of action against neurological conditions. The analogues were compared with SFX-01, the Company's lead product (a synthetic, stabilised form of sulforaphane), which is in two Phase 2 clinical studies for breast cancer and subarachnoid haemorrhage.
  • 21 of the analogues were shown to be twice as toxic against breast-cancer cells compared to SFX-01, with one analogue demonstrating eight-fold toxicity. No analogue was as potent as SFX-01 as an activator of Nrf2.
  • The screening has identified candidates which merit further investigation as anti-cancer agents. It also provides reassurance that SFX-01 remains the optimal sulforaphane-based drug candidate for subarachnoid haemorrhage and potentially other neurological indications.

The screening highlights potential candidates for the Company pipeline and underlines the Company's strategy to secure a leading position in sulforaphane-based drugs. However, Evgen remains primarily focused on the clinical trials of SFX-01 and recognises that near-term progression of the analogues will likely be through collaborations that can lever non-dilutive grant funding. Both the ongoing Phase 2 trials are due topline readouts by the end of 2018.


1. Northland Capital Partners Limited (“Northland”) acts as Nominated Advisor and/or Broker to the company.

2. Northland) and/or its affiliates companies do beneficially own 1% or more of any class of the issuer’s equity securities, as of the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month. 

3. The authoring analyst or any associate of the authoring analyst does maintain a long or short position in any of the issuer’s securities directly or through derivatives, including options or futures positions.

4. Northland, its affiliated companies, partners, officers, directors or any authoring analyst of Northland has provided services to the issuer for remuneration during the preceding 12 months other than investment advisory or trading services.

5. Northland or any of its affiliated companies has performed investment banking services for the issuer during the 12 months preceding the date of issuance of the report.  

6. A partner, director, officer, employee or agent of Northland or any of its affiliated companies is an officer, director, employee or advisor of the issuer.  Disclosures are applicable for all companies

7. The authoring analyst, or any associate of the authoring analyst, has viewed the material operations of the issuer. 

8. The authoring analyst, or any associate of the authoring analyst, received reimbursement for travel expenses.

9. Northland makes a market in the securities of this company.




This document is provided solely to enable clients to make their own investment decisions. It may therefore not be suitable for all recipients and does not constitute a personal recommendation to invest. It does not constitute an offer or solicitation to buy or sell securities or instruments of any kind. If you have any doubts about the suitability of this service, you should seek advice from your investment adviser. This document is produced in accordance with UK laws and regulations. It is not intended for any person whose nationality or residential circumstances may render its receipt unlawful.

The past is not necessarily a guide to future performance. The value of shares and the income arising from them can fall as well as rise and investors may get back less than they originally invested. The information contained in this document has been obtained from sources which Northland Capital Partners Limited believes to be re¬li¬able. The Com¬pany does not warrant that such information is accurate or complete. All estimates and prospective figures quoted in this report are forecasts and not guaranteed. Opinions included in this report reflect the Company’s judgement at the date of publication and are subject to change without notice. If the investment(s) mentioned in this report are denominated in a currency different from the currency of the country in which the recipient is a resident, the recipient should be aware that fluctuations in exchange rates may have an adverse effect on the value of the investment(s). The listing requirements for securities listed on AIM or PLUS markets are less demanding, also trading in them may be less liquid than main markets.

Northland Capital Partners Limited and/or its officers, as¬sociated entities or clients may have a position, or other material interest, in any securities men¬tioned in this report. Northland Capital Partners Limited does not provide recommendations on securities of firms with which it has a corporate relationship. More information about our management of Conflicts of Interest, Investment Research Methodology & Definition of Recommendations can be found at 

Northland Capital Partners Limited is authorised and regulated by the Financial Conduct Authority and a Member of the London Stock Exchange.

Published by/copyright: Northland Capital Partners Limited, 2013. All rights reserved

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use